Physician profile
Edward Kuo
NPI 1700992310
$4,632.28
in general payments reported to CMS, 2019-2025
24 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $794 · 2021: $861 · 2022: $652 · 2023: $625 · 2024: $659 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,539.76 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $927.71 | 2021-2025 | |
| Lilly USA, LLC | $564.79 | 2019-2025 | Mounjaro |
| Gilead Sciences, INC. | $303.56 | 2020-2025 | |
| Allergan, INC. | $258.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $159.39 | 2019-2024 | Trelegy Ellipta |
| Bausch Health US, LLC | $133.86 | 2020-2021 | |
| Pfizer INC. | $113.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.64 | 2020-2023 | Trulance, Xifaxan |
| Nestle Healthcare Nutrition INC. | $93.60 | 2021-2022 | |
| Vertiflex, INC. | $67.77 | 2019 | |
| Eisai INC. | $67.73 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $50.00 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $45.93 | 2019-2021 | |
| Exact Sciences Corporation | $41.10 | 2023-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.40 | 2022 | |
| Merck Sharp & Dohme LLC | $22.04 | 2020 | |
| Abbott Laboratories | $21.80 | 2022 | |
| Inspire Medical Systems, INC. | $18.99 | 2023 | Inspire |
| Ibsa Pharma INC. | $15.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.